{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-056911","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.748502+00:00","generated_at":"2026-05-18T22:50:11.882692+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OS Therapies (OSTX) raises up to $8M via warrant exercise inducement; extends cash runway into H2 2026","bullets":["Holders exercise 1.57M old warrants ($1.12) for cash; receive new 5-year warrants at $3.00/sh.","Gross proceeds up to ~$8M; $1.76M already received, extending cash runway into H2 2026.","Proceeds to support regulatory/pre-commercial efforts for OST-HER2 in osteosarcoma.","Offering period June 20 to July 10, 2025; solicitation agent fee 5% of gross proceeds.","Company reiterates BLA submission to FDA in Q3 2025; potential PRV sale (most recent at $160M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-056911","json":"https://secwatch.observer/filing/0001213900-25-056911.json","markdown":"https://secwatch.observer/filing/0001213900-25-056911.md","text":"https://secwatch.observer/filing/0001213900-25-056911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/0001213900-25-056911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/ea0246590-8k_ostherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:50:11.882692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}